PriceTargets.com logo

Tyra Biosciences - TYRA Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $22.00
  • Forecasted Upside: 42.49%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$15.44 As of 04/25/2024 11:34 AM ET
▼ -0.56 (-3.50%)

This chart shows the closing price for TYRA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Tyra Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TYRA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TYRA

Analyst Price Target is $22.00
▲ +42.49% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Tyra Biosciences in the last 3 months. The average price target is $22.00, with a high forecast of $28.00 and a low forecast of $15.00. The average price target represents a 42.49% upside from the last price of $15.44.

This chart shows the closing price for TYRA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 3 contributing investment analysts is to moderate buy stock in Tyra Biosciences. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/21/2024WedbushReiterated RatingOutperform ➝ Outperform$28.00Low
3/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$19.00 ➝ $23.00Low
12/29/2023WedbushReiterated RatingOutperform ➝ Outperform$27.00Low
12/26/2023HC WainwrightReiterated RatingBuy ➝ Buy$19.00Low
12/15/2023Bank of AmericaDowngradeBuy ➝ Neutral$25.00 ➝ $15.00Low
11/7/2023HC WainwrightLower TargetBuy ➝ Buy$20.00 ➝ $19.00Low
8/11/2023WedbushReiterated RatingOutperform ➝ Outperform$27.00Low
8/11/2023HC WainwrightBoost TargetBuy ➝ Buy$17.00 ➝ $20.00Low
8/1/2023HC WainwrightReiterated RatingBuy ➝ Buy$17.00Low
6/29/2023WedbushInitiated CoverageOutperform$27.00Low
3/23/2023HC WainwrightReiterated RatingBuy$17.00Low
3/2/2023HC WainwrightBoost TargetBuy$12.00 ➝ $15.00Low
3/1/2023OppenheimerBoost Target$17.00 ➝ $25.00Low
2/2/2023OppenheimerInitiated CoverageOutperform$17.00Low
6/23/2022HC WainwrightInitiated CoverageBuy$12.00Low
3/8/2022Jefferies Financial GroupUpgradeHold ➝ Buy$31.00 ➝ $27.00High
11/8/2021Jefferies Financial GroupReiterated RatingBuy ➝ Hold$19.00 ➝ $31.00Low
10/11/2021Bank of AmericaInitiated CoverageBuy$22.00High
10/11/2021Jefferies Financial GroupInitiated CoverageBuy$19.00High
10/11/2021CowenInitiated CoverageOutperformHigh
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.85 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 9 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 9 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Tyra Biosciences logo
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Read More

Today's Range

Now: $15.44
Low: $14.87
High: $16.15

50 Day Range

MA: $17.53
Low: $14.45
High: $20.00

52 Week Range

Now: $15.44
Low: $10.38
High: $20.67

Volume

11,089 shs

Average Volume

129,251 shs

Market Capitalization

$810.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12

Frequently Asked Questions

What sell-side analysts currently cover shares of Tyra Biosciences?

The following equities research analysts have issued research reports on Tyra Biosciences in the last year: Bank of America Co., HC Wainwright, and Wedbush.
View the latest analyst ratings for TYRA.

What is the current price target for Tyra Biosciences?

3 Wall Street analysts have set twelve-month price targets for Tyra Biosciences in the last year. Their average twelve-month price target is $22.00, suggesting a possible upside of 42.5%. Wedbush has the highest price target set, predicting TYRA will reach $28.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $15.00 for Tyra Biosciences in the next year.
View the latest price targets for TYRA.

What is the current consensus analyst rating for Tyra Biosciences?

Tyra Biosciences currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for TYRA.

What other companies compete with Tyra Biosciences?

Other companies that are similar to Tyra Biosciences include 89bio, OPKO Health, Arcutis Biotherapeutics, Immunome and Cassava Sciences. Learn More about companies similar to Tyra Biosciences.

How do I contact Tyra Biosciences' investor relations team?

Tyra Biosciences' physical mailing address is 2656 STATE STREET, CARLSBAD CA, 92008. The company's listed phone number is 619-728-4760 and its investor relations email address is [email protected].. The official website for Tyra Biosciences is www.tyra.bio. Learn More about contacing Tyra Biosciences investor relations.